50% of the country is ranked in the top 50%. Its hard to sell for 50% of the people.
Pretty terrible
A college friend works as an investment planner now, and he was showing me some of the analyst reports for aclidinium...it's not pretty. The entire class is moving to once daily and this product clearly failed. He said the analysts were all over that. Also, nearly every other competitor has outcomes...ugh.
Dumb ass with the friend who has the friend working as a grunt for Edward Jones, tell me something. What outcomes data? Nothing has ever proven to impact mortality? Also, what is with the once a day stuff? That is Spirivas weakness. You lose effect at night.
"oh gee, I don't want to take a second puff of an inhaler at night (which I am already doing with my Advair). I want to have symptoms at 3 am."
Aclidinium will be priced less too.
Is today dumb ass day on this board?
A college friend works as an investment planner now, and he was showing me some of the analyst reports for aclidinium...it's not pretty. The entire class is moving to once daily and this product clearly failed. He said the analysts were all over that. Also, nearly every other competitor has outcomes...ugh.
A college friend works as an investment planner now, and he was showing me some of the analyst reports for aclidinium...it's not pretty. The entire class is moving to once daily and this product clearly failed. He said the analysts were all over that. Also, nearly every other competitor has outcomes...ugh.
And another question for your dumb dumb financial planner (who probably wishes his $40k a year ass could have gotten a drug rep job instead of calling everyone he has ever known in his life to get them to open an IRA) - besides Spiriva, Daliresp and Theodur whoch COPD meds are once a day?
He said that gsk will launch once daily relovair next yr with outcomes.. The whole market is going that way. Bring on the layoffs
Ill be a coffee carrier for 70k any day, beats punching a clock hands down.